Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in June 2014 on request of the Sponsor.

On 18 December 2002, orphan designation (EU/3/02/126) was granted by the European Commission to Dyax s.a., Belgium, for recombinant inhibitor of human plasma kallikrein for the treatment of angioedema.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Recombinant inhibitor of human plasma kallikrein
Disease / condition
Treatment of angioedema
Date of first decision
EU designation number

Sponsor's contact details

Dyax s.a.
159B Oudemoeder
4880 Aubel
Tel. +32 87 688118
Fax +32 87 688918

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating